EN | RU
EN | RU

Help Support

Back

Plaque psoriasis patients experience high satisfaction with topical Cal/BD therapy

Plaque psoriasis patients experience high satisfaction with topical Cal/BD therapy Plaque psoriasis patients experience high satisfaction with topical Cal/BD therapy
Plaque psoriasis patients experience high satisfaction with topical Cal/BD therapy Plaque psoriasis patients experience high satisfaction with topical Cal/BD therapy

What's new?

A cutaneous foam of calcipotriol/betamethasone dipropionate improves patient satisfaction in people with plaque psoriasis.

In a real-practice setting, a cohort of plaque psoriasis patients was found to be highly satisfied with the topical treatment of calcipotriol/betamethasone dipropionate (Cal/BD) in a study published in Dermatologic Therapy. Researchers undertook this multicenter, observational prospective cohort 4-week study to investigate participant's satisfaction with cutaneous foam of Cal/BD in a real-life dermatological clinical practice.

The LION study recruited adults (mean age 55.6 years, 59.4% males) having plaque psoriasis on the scalp and/or body. The primary endpoint was therapy satisfaction as evaluated by the 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9). Secondary endpoints included: (i) preference over prior therapies by Patient Preference Questionnaire (PPQ), (ii) alteration in disease state by Psoriasis Area Severity Index (PASI), and (i) factors associated with satisfaction from Cal/BD foam therapy.

In total, 256 patients were eligible. The psoriasis severity was found to be severe in 4.7%, mild in 52% of participants, and moderate in 43.3%. In 36.7% of people, scalp involvement was noted to be present. About 80.5% of patients had received prior antipsoriatic therapies. The TSQM-9 median scores for effectiveness, convenience, and global satisfaction is illustrated in Table 1:


After four weeks, the mean (Standard Deviation, SD) PASI value dropped from 7.3 (4.8) to 2.1 (2.7), as shown in Figure 1:


Majorly, its effectiveness and convenience were appreciated, regardless of whether patients were treatment naïve or had already been treated for psoriasis. In addition, those who had received prior therapies reported a high preference for the Cal/BD foam over previous topical therapies.

Greater than 90% of individuals previously treated for psoriasis found the Cal/BD foam to be more effective, easier to use and well-tolerated than prior topical therapies at PPQ. Thus, the study yielded real-life evidence of better satisfaction, convenience and efficacy of Cal/BD for treating plaque psoriasis, with an objective improvement in PASI.

Source:

Dermatologic Therapy

Article:

Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis: the LION real-life multicenter prospective observational cohort study

Authors:

Campanati Anna et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: